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Summary Chromosomal aberrations of 20 stage 4s neuroblastomas were analysed by comparative genomic hybridization (CGH). In a
subset of 13/20 tumours, telomerase activity was evaluated by the telomeric repeat amplification protocol (TRAP). The CGH data were
compared with the CGH results of ten stage 1 and 2 (stage 1/2) and 22 stage 3 and 4 (stage 3/4) neuroblastomas. A total of 17/20 stage 4s
neuroblastomas did not progress clinically, whereas tumour progression with lethal outcome occurred in 3/20 cases. The CGH data of
clinically non-progressing stage 4s tumours revealed a high rate of whole-chromosome aberrations (73.4%) with an overrepresentation of
mainly chromosomes 2, 6, 7, 12, 13, 17, 18 and an underrepresentation of mainly chromosomes 3, 4, 11, 14. MYCN amplification or lp
deletion was observed in only 1/27 or 2/17 clinically non-progressing stage 4s tumours respectively, whereas all three progressive stage 4s
neuroblastomas showed MYCN amplification, 1p deletion and, in 2/3 cases, distal 17q gains. Exceptfor one case, telomerase activity was not
observed in non-progressing stage 4s neuroblastomas. In contrast, 4s tumours with lethal outcome revealed elevated telomerase activity
levels. Our data suggest that stage 4s neuroblastomas belong to two biologically different groups, one of which displays the genetic features
of localized stage 1/2 tumours, whereas the other mimics advanced stage 3/4 neuroblastomas.
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Neuroblastoma, one of the most common solid tumours in child-
hood, varies widely in clinical behaviour, ranging from differenti-
ation or spontaneous regression to malignant progression with
lethal outcome. The extreme heterogeneity of neuroblastoma is
best reflected in the clinical subgroup of4s tumours. According to
the revised international staging system, stage 4s ('s' for special) is
restricted to neuroblastoma patients (patient age < 1 year) with
tumour distribution in the liver, skin and/orbone marrow (Brodeur
et al, 1993). Whereas most 4s neuroblastomas are known to
undergo spontaneous regression independently ofanti-cancer ther-
apies, some tumours later progress to stage 4 tumours (Bourhis et
al, 1991; Wilson et al 1991). In advanced neuroblastomas of the
clinical stages 3/4, lp deletion and MYCN amplification were
shown to be the most important prognostic indicators. In contrast
to stage 3/4 tumours, genetic data on stage 4s neuroblastomas are
scarce, although they represent as many as 10% ofneuroblastomas
(Balaban and Gilbert, 1983; Hayashi et al, 1989). Studies focusing
on the prognostic value of lp deletion and MYCN amplification
revealed contradictory results for the group of stage 4s neuroblas-
tomas (Nakagawara et al, 1990; Bourhis et al, 1991; Tonini et al,
1997). Because of the small number of cases studied, the genetic
features ofstage 4s neuroblastomas are by no means clear yet. The
assessment of telomerase activity levels as markers of in vivo
immortalization and metastatic potential has gained in importance
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over recent years (Healy, 1995). The data of a recent study by
Hiyama et al (1995) have indicated a possible prognostic rele-
vance oftelomerase activity for neuroblastomas.
Recent studies, including a study from our own laboratory, have
shown that comparative genomic hybridization (CGH), which was
introduced by Kallioniemi et al (1992), serves as an ideal method
to give a comprehensive picture of the major genetic imbalances
in clinically advanced neuroblastomas (Altura et al, 1997;
Brinkschmidt et al, 1997; Lastowska et al, 1997; Plantaz et al,
1997). In this retrospective study, we analysed 20 4s tumours in
order to reveal currently unknown chromosomal alterations ofthis
enigmatic subgroup of neuroblastoma. An analysis of telomerase
activity was performed in 13/20 cases.
MATERIALS AND METHODS
Patients
Snap-frozen specimens of 20 4s neuroblastomas (untreated
primary tumours), obtained from paediatric hospitals participating
in the German Neuroblastoma Trial, were analysed. The clinical
characteristics with follow-up data as well as the MYCN status
(studied by semiquantitative Southern blot hybridization) are
listed in Table 1. The CGH results were compared with CGH data
of 22 clinically advanced neuroblastomas of stage 3/4 (medium
age 47.3 months, range 10.9-95.7) and ten localized neuroblas-
tomas of clinical stage 1/2 (medium age 16.9 months, range
0.03-48.8). CGH data of stage 1/2 and stage 3/4 tumours as well
as 2/20 stage 4s tumours have already been reported
(Brinkschmidt et al, 1997). Staging was performed according to
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Figure 1 Telomerase activity in two different 4s neuroblastomas with high (upper lane) and low telomerase activity (lower lane), analysed by the telomeric
repeat amplification protocol (TRAP). An internal PCR-control generating a peak of 36 base pairs (bp) is included in each assay. Peak height and peak area of
the internal control increase with decreasing telomerase activity levels and vice versa. Seven of more than 20 telomerase amplification products of 50 bp, 56 bp,
62 bp, etc. are shown in each lane. Each fluorescent peak was quantified in terms of size (bp), peak height and peak area
the International Neuroblastoma Staging System (Brodeur et al,
1993). Patients were treated in conformity with treatment proto-
cols given in the German Neuroblastoma Trial. Only tumour
samples that had been shown histologically to contain more than
50% of tumour cells were analysed.
CGH analysis
DNA was isolated by phenol-chloroform extraction according to
standard protocols. With minor modifications, CGH analysis was
performed as described by du Manoir et al (1993). Briefly, tumour
DNA was labelled with biotin-16-dUTP (Boehringer Mannheim)
and reference DNA from a healthy male donor was labelled with
digoxigenin- 1 -dUTP (Boehringer Mannheim) in a standard nick
translation reaction. The DNAase I concentration in the labelling
reaction was adjusted in order to reveal an average fragment size
of 500-1000 base pairs. The labelled DNA fragments were
purified from remaining nucleotides by column chromatography
(Sephadex-G50).
For CGH, 500 ng of tumour DNA, 300 ng of reference DNA
and 30 .tg of human Cot1 DNA (Gibco) were co-precipitated and
redissolved in 10pg of hybridization buffer. Denaturation of DNA
(75°C for 5 min) was followed by a preannealing time of 45 min
at 37°C. Target metaphase spreads (46,XY), which had been
prepared following standard procedures, were denatured sepa-
rately in 70% formamide/2xSSC for 2 min at 72°C. Hybridization
was allowed to proceed for 3-4 days. A subset ofexperiments was
performed on commercially available metaphase spreads (Vysis).
The denaturation of these slides was performed according to the
manufacturer's instructions.
Post-hybridization washes were carried out to a stringency
of 50% formamide/2 x SSC at 45°C and 0.1 x SSC at 600C.
Biotinylated and digoxigenated sequences were detected simulta-
neously, using avidin-FITC (Boehringer, 1:200) and anti-
digoxigenin-rhodamine (Boehringer, 1:40). The slides were
counterstained with DAPI and mounted in an antifade solution
(Vectashield, Vector laboratories).
MicroscopyandDigital Image Analysis
Separate digitized grey level images of DAPI, FITC and
rhodamine fluorescence were taken with a charge coupled device
(CCD) camera (Cohu 6X-924) connected to a Leica DMRBE
microscope. The image processing was carried out by use of
Applied Imaging Software. Average green-red ratios were calcu-
lated for each chromosome in 5-10 metaphases.
Statistical thresholds and controls
Chromosomal regions with CGH ratio profiles surpassing the 50%
CGH thresholds (upper threshold 1.25, lower threshold 0.75) were
defined as loci with copy number gains or losses. Based on experi-
ments with normal control DNA, these thresholds have been
proved to eliminate false-positive results. However, some tumours
revealed significant shifts of the ratio profiles towards gains or
losses not surpassing the 50% thresholds. As 50% thresholds were
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Figure 2 Overview of all gains (right) and losses (left) of genetic material in stage 4s neuroblastomas in comparison with CGH results of ten stage 1/2 tumours
and 22 stage 3/4 neuroblastomas. Entire X and Y chromosomes were excluded from data analysis (see Materials and methods)
designed for diploid tumours (du Manoir et al, 1995), genetic
imbalances of hyperdiploid tumours may be within these thresh-
olds. Significant CGH ratio profile shifts within the 50% thresholds
were therefore taken into account in our data analysis, on condition
that the 95% confidence limits did not touch the central line of the
balanced state. Genetic imbalances that most often met the latter
criteria were represented by whole-chromosome abnormalities,
which are frequently seen in hyperdiploid tumours. Previous
reverse hybridization experiments confirmed the consistency of
these aberrations. Moreover, significant CGH ratio profile shifts
with 95% confidence limits that did not touch the central line were
not observed in control hybridizations of differentially labelled
normal DNA, which were included in each CGH experiment.
Control hybridizations on target metaphase spreads purchased
from Vysis occasionally revealed false-positive results simultane-
ously involving chromosomes lp, 16 and 19. Copy number abnor-
malities revealing this aberration pattern were therefore excluded
from data analysis. As the tumour specimens and normal DNA
were not sex matched, entire X and Y chromosomes were
excluded.
Telomerase assay
Extracts of tissue specimens were prepared according to a modi-
fied Kim's procedure, as described elsewhere (Poremba et al,
1997). Briefly, frozen tissue samples ofapproximately 50 mg were
homogenized in 100 pl ofCHAPS lysis buffer. After 30 min incu-
bation on ice, the lysates were centrifuged at 12 500g for 30 min
at 4°C. The supernatant was frozen rapidly in liquid nitrogen
and stored at -80°C. The concentration of protein was measured
using the Coomassie Protein Assay Reagent (BioRad, USA) and
adjusted to 2 ,ug 1.-'
For the in vitro detection of telomerase activity, a modified
version of the TRAP assay was used (Poremba et al, 1997). In
brief, 1 gl ofeach tissue extract (containing 2 jig ml-' protein) was
suspended in 24 ,ul ofreaction mix containing 2.5 pl of 10 x reac-
tion buffer (200 mm Tris-HCl, pH 8.3, 15 mM MgCl2, 630 mM
KCl, 0.5% Tween 20, 10 mM ethylene glycol-bis [3-aminoethy
ether)-N,N,N',N'-tetraacetic acid (EGTA), 0.1% BSA], 0.5 pl of
50 x dNTP mix (2.5 mm each dATP, dTTP, dGTP, dCTP), 0.2 ,l of
Taq-polymerase (5 U ml-', Perkin-Elmer, Branchburg, NJ, USA),
19.8 pl of PCR-grade ddH20, 0.25 pl (15 gM), fluorescence-
labelled TS forward primer [5'-(Cy-5)-AATCCGTCGAG-
CAGAGTT-3, Pharmacia, Freiburg, Germany] and 0.25 pl of
Cx reverse primer (5'-CCCTTACCCTTACCCTTACCCTTA-3').
Each reaction mixture contained an internal PCR amplification
control (TRAPeze telomerase detection kit, Oncor, Gaithersburg,
MD, USA), producing a 36-bp product, which was co-amplified
with telomerase-elongated products in each reaction. Each
analysis included a telomerase-positive control (Ewing's tumour
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Table 1 Molecular cytogenetic data, telomerase activity and clinical outcome in 20 stage 4s neuroblastomas
Follow-upa MYCNb MYCNC del 1pd Chromosome 17e Telomerase'
Case Age (months) (months) (Southern) (CGH) (CGH) (CGH)
1 2.5 18 1 - + +17q ND
2 1.3 18t 10 + + - +
3 10 75 1 - - +g ND
4 3.2 69 1 - --
5 4 0,9t 10 + + +17q +
6 5.5 55 1 - - +g -
7 2.4 64 1 - - +g -
8 0.5 75 10 + + +17q +
9 7 13 1 - - +g -
10 0.7 57 1 - - - -
11 2 49 1 - - +g ND
12 0.4 45 1 - - +g ND
13 2.7 22 1 - - +g -
14 8.3 40 1 - - +g ND
15 4.5 9t 30 + + +17q +++
16 0.3 20 1 - - +g -
17 2 23 1 - - - n.d.
18 2.5 3 1 - - +g -
19 3.6 7 1 - - +g -
20 7.5 6 1 - - +g -
aLethal outcome (t) x months after tumour diagnosis. bSemiquantitative evaluation of MYCN copy numbers analysed by Southern blot analysis. cDetection (+) of
high-level DNA copy number increases at the MYCN locus (2p23-24) by CGH. dDetection (+) of DNA sequence losses on chromosome 1p by CGH. eDetection
(+g) of gain of whole-chromosome 17 by CGH. fDetection (+) of low telomerase activity in the TRAP assay; +++, detection of high telomerase activity; ND not done
Figure 3 Example of a two-colour probe image (tumour labelled in green, reference DNA labelled in red) of a progressing stage 4s neuroblastoma
characterized by high-level copy number increases at the MYCN locus (2p23-24) and losses of the distal part of chromosome 1p. Right, the average CGH ratio
profile of chromosome 1 and 2 with the 95% confidence limits. The black line on the ratio profile reflects a balanced state, whereas the first green and red lines
represent the 50% thresholds (du Manoir et al 1995)
cell line VH-64), heat-inactivated controls (telomerase-positive of amplification products, 1 gl of PCR product and 6.7 gl of
control incubated at 94°C for 5 min before reaction) and a negative loading buffer (90% formamide, 10% dextran blue) were mixed
control (CHAPS-lysis buffer instead of sample). For the analysis and denatured at 94°C for 5 min. Aliquots of 6 ,ul were loaded on
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to denaturing 8% polyacrylamide gels on an automated laser fluo-
rescence sequencer (ALFexpress, Pharmacia, Freiburg, Germany)
and subjected to electrophoresis. Fluorescence data were collected
automatically and analysed by the Fragment Manager Program
Version 1.02 (Pharmacia). Each fluorescent peak was quantified in
terms of size (base pairs), peak height and peak area in relation to
the positive telomerase control: no telomerase activity (-); low
telomerase activity (<30% of positive control); intermediate
telomerase activity (30-70% of positive control); high telomerase
activity (>70% ofpositive control).
In order to minimize the possibility of false-negative results
with a lack of or low telomerase activity owing to tissue degrada-
tion and necrosis, RNA derived from frozen sections was ampli-
fied by reverse-transcriptase PCR (rt-PCR) for f-actin as an
indirect marker of tissue viability (Figure 1). Briefly, a 495-bp
fragment of the human,-actin gene was amplified with primers
5'-CATGCCATCCTGCGTCTGGAC-3' and 5'-CACGGAGTA-
CTTGCGCTCAGGAGG-3'. as described elsewhere (Dockhorn-
Dworniczak et al, 1994).
Loss of heterozygosity (LOH) study (detection of 1 p36
deletion)
Constitutional DNA isolated from blood mononuclear cells of
28/52 neuroblastoma patients was used as a control for interpreting
LOH observed in the tumour tissue (9/20 4s cases; 3/10 stage 1/2
cases; 16/22 stage 3/4 cases). The loci D1S80 and D1S76
containing a variable number of tandem repeats (VNTR) were
PCR amplified as detailed in Brinkschmidt et al (1997). LOH
study results of stage 3/4 and stage 1/2 cases as well as 2/20 stage
4s tumours have been reported before (Brinkschmidt et al, 1997).
RESULTS
Figure 2 gives an overview of all CGH results of the 20 clinical
stage 4s neuroblastomas in comparison with ten tumours of clin-
ical stage 1/2 and 22 tumours of clinical stage 3/4. Genetic aberra-
tions involving at least three different autosomes were observed in
all but four tumours (two tumours either of stage 4s or stage 1).
The average number of genetic alterations detected by CGH was
9.2 per tumour (range 0-15) for the group of stage 4s patients, 8.9
per tumour (range 0-14) for clinical stage 1/2 patients and 7.4 per
tumour (range 3-11) for clinical stage 3/4 patients.
CGH of 4s tumours and localized stage 1/2 tumours revealed a
much higher percentage of chromosome abnormalities involving
the entire chromosome length (stage 4s 73.4%, stage 1/2 78.7%)
compared with advanced stage 3/4 tumours (36.2%), which were
characterized by a high rate of segmental aberrations. There was a
strong predeliction of certain chromosomes to be overrepresented
(chromosomes 2, 6, 7, 12, 13, 17, 18) or underrepresented (chro-
mosomes 3, 4, 11, 14). As can be seen in Figure 2, this pattern of
whole-chromosome abnormalities occurred irrespective of the
tumour stage.
The most frequent genetic aberration of all three groups
detected by CGH was observed on chromosome 17 (stage 4s 80%,
stage 1/2 80%, stage 3/4 77%). In contrast to stage 3/4 cases, chro-
mosome 17 imbalances of non-progressing stage 4s and stage 1/2
tumours were mostly represented by whole-chromosome gains
(stage 4s 75%, stage 1/2 87.5%, stage 3/4 11.8%). Distal 17q gains
were observed in two out of three progressing 4s neuroblastomas
(Table 1).
Table 1 summarizes the clinical data of stage 4s patients,
the CGH and Southern blot results of MYCN amplification, lp
deletion, chromosome 17 imbalances as well as the results of
telomerase activity analysis. CGH of stage 4s neuroblastomas
revealed high-level copy number increases at the MYCN locus
(2p23-24) in 4/20 cases (stage 1/2, 1/10; stage 3/4, 16/22) and
segmental DNA sequence loss of chromosome lp was observed in
5/20 stage 4s tumours (stage 1/2, 0/10; stage 3/4, 11/22) (Table 1).
The Southern blot analysis of MYCN amplification was consistent
with CGH data. Clinically progressing 4s neuroblastomas were
uniformly characterized by MYCN amplification, lp deletion
(Figure 3) and elevated telomerase activity levels (Table 1). Apart
from one case, which showed MYCN amplification, lp deletion
and low telomerase activity (no. 8, Table 1), all other non-
progressing 4s neuroblastomas lacked telomerase activity. The
average number ofchromosomal aberrations in telomerase-positive
cases was not significant compared with telomerase negative stage
4s neuroblastomas (telomerase positive cases, 5.25 aberrations per
tumour, range 2-9; telomerase negative cases, 9.0 aberrations per
tumour, range 0-15).
Apart from MYCN amplification, other regional high-level
copy number increases were not detected in stage 4s tumours.
High-level copy number increases at 2p 13-14 and 3q24-26,
observed in two stage 4 neuroblastomas, have previously been
described (Brinkschmidt et al, 1997).
The LOH 1p36 study revealed allelic losses on distal minisatel-
lite loci DIS80 and D1S76 in four cases (two cases of stage 4s,
two cases of stage 3), all of which showed lp deletion in the CGH
analysis. A total of 19/28 cases studied retained heterozygosity for
both loci, whereas five cases were not informative. Except for one
case, CGH results were consistent with LOH analysis.
DISCUSSION
Stage 4s neuroblastoma was originally defined to identify patients
with an excellent prognosis irrespective of an obvious tumour spread
at the time of diagnosis (D'Angio et al, 1971; Evans et al, 1971). In
the meantime, it has become evident that up to 25% of 4s neuro-
blastomas do, after all, show tumour progression (Suarez et al, 1991).
In our series, 3/20 4s neuroblastoma patients died of their disease.
Compared with the non-progressing neuroblastomas, the tumours of
these patients showed strikingly different biological characteristics.
These included MYCN amplification and lp deletion, the most
powerful prognostic markers in advanced-stage neuroblastomas
(Seeger et al, 1985; Christiansen and Lampert, 1988; Caron et al,
1996), as well as 17q imbalances and telomerase activity.
Ever since the first description of MYCN amplification in a 4s
neuroblastoma by Tonini et al (1987), the usefulness of MYCN
amplification and 1p deletion as prognostic markers has been
questioned for 4s neuroblastomas (Nakagawara et al, 1990; Tonini
et al, 1997). Yet, all three fatal cases of our study showed MYCN
amplification and lp deletion. These findings corroborate the
strong predictive value of these markers for the clinical subgroup
of stage 4s tumours, which has also been described by Ambros et
al (1995), Caron (1995) and Bourhis et al (1991).
The reliability ofCGH for the detection of Ip deletions has been
contentious (Kallioniemi et al, 1994). Recent studies with polymor-
phic markers as well as fluorescence in situ hybridization (FISH)
studies have nevertheless confirmed CGH-detected lp deletions
(Brinkschmidt et al, 1997; Lastowska et al, 1997). In the present
study, constitutional DNA was available fortwo out offourstage 4s
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cases with CGH-detected Ip deletion and MYCN amplification. As
expected, LOH lp36 was observed in both cases.
Recently published CGH and FISH studies on neuroblastoma
indicated that aberrations of chromosome 17 play a major role in
the biology ofthese tumours (Brinkschmidt et al, 1997; Lastowska
et al, 1997; Plantaz et al, 1997). Distal chromosome 17q gains
were shown to be characteristic of advanced stage 3/4 tumours
(Meddeb et al, 1996). In our series, distal chromosome 17q gains
were accordingly observed in two out ofthreeprogressing stage 4s
tumours, whereas the majority ofnon-progressing tumours (13/17
cases) revealed gains ofthe entire chromosome 17.
Poor prognostic markers were detected in only 2/17 non-
progressing cases. One patient (no. 8, Table 1), still in remission
61 months after diagnosis, showed MYCN amplification, lp
deletion and low-level telomerase activity. Owing to the initial
detection of MYCN amplification, aggressive chemotherapy was
performed, which may have improved the prognosis. The second
patient (no. 1, Table 1), who experienced an inconspicuous 18-
month follow-up period, showed lp deletion and a segmental
distal 17q gain, but no MYCN amplification or telomerase
activity. Therapy did not differ from the non-progressing tumour
group. However, long-term observation of both patients will be
vital for detecting possible deviations from the genetically incon-
spicuous patient group.
As regressing cells do not normally grow in culture, few cytoge-
netic data on 4s tumours are available. In short-term cell culture
studies by Hayashi et al (1989) similar chromosomal aberration
patterns were observed in five stage 4s neuroblastomas and 23
localized stage 1/2 neuroblastomas. This is in accordance with our
data showing the same rates and patterns of whole-chromosome
abnormalities for these tumour stages. Although the exact ploidy
rates oftumours cannot be obtained by CGH, a high rate ofwhole-
chromosome abnormalities most possibly reflects relative losses
or gains of entire chromosomes in hyperdiploid karyotypes. This
hypothesis is consistent with our CGH data as well as those of
Plantaz et al (1997), which revealed a high rate of whole-chromo-
some abnormalities in non-progressing stage 4s and stage 1/2
tumours. These tumours have regularly been shown to be triploid
in flow cytometric and FISH studies (Ambros et al, 1996),
whereas advanced stage 3/4 neuroblastomas are mostly diploid
(Look et al, 1991).
The whole-chromosome abnormalities observed in our study
were not random. Notably, there was a strong predilection of
certain chromosomes to be overrepresented (chromosomes 2, 6, 7,
12, 13, 17, 18) or underrepresented (chromosomes 3, 4, 11,14).
This predeliction was observed not only in stage 4s or localized
stage 1/2 tumours, but also in the advanced stage 3/4 neuro-
blastomas. In their recently published CGH studies, Lastowska et
al (1997) and Plantaz et al (1997) found almost the same pattern of
whole-chromosome abnormalities irrespective of tumour stage.
The resulting characteristic chromosomal pattern might be
attributed to selective pressure as a result of gene function(s) on
additional chromosomes that provide cells with these extra
chromosomes with a growth advantage (Plantaz et al, 1997).
Telomerase activity was absent in all 16/20 non-progressive 4s
tumours. This corresponds to the data ofHiyama et al (1995), who
analysed the telomerase activity of 100 neuroblastomas (among
them eight stage 4s tumours). Whereas in their study low-level
telomerase activity was mostly restricted to favourable neuro-
blastomas, two out of three unfavourable 4s tumours of our series
exhibited low telomerase activity. We observed high telomerase
activity in only one progressive tumour. In contrast to Hiyama's
series, neuroblastomas with low telomerase activity did, however,
show additional genetic changes such as MYCN amplification and
lp deletion. Hence, telomerase activity in these tumours is more
probably due to reactivation of the enzyme caused by additional
genetic changes than reflecting telomerase activity from remnants
of neuroblasts.
In summary, our data indicate that stage 4s neuroblastoma repre-
sents a clinical aggregation of two biologically different tumour
groups. Whereas non-progressing 4s tumours characterized by a
distinct pattern of whole-chromosome abnormalities seem to be
within the same molecular cytogenetic category as localized stage
1/2 neuroblastomas, clinically progressing 4s neuroblastomas share
the characteristic cytogenetic features of disseminated stage 3/4
tumours. In contrast to regressing 4s tumours, progressing 4s
neuroblastomas are moreover associated with detectable telom-
erase activity. Thus, molecular cytogenetic analysis by CGH and
detection of telomerase activity may open new modalities of
predicting the outcome of 4s neuroblastomas, which could then
lead to an individual risk-adapted treatment strategy.
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